JANX
Company Description
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 10.00M | 10.59M | 8.08M | 8.61M | 3.64M | 0 | 0 |
| Net Income | (113.62M) | (68.99M) | (58.29M) | (63.06M) | (32.67M) | (6.78M) | (4.24M) |
| EPS | -1.83 | -1.28 | -1.32 | -1.52 | -0.79 | -0.16 | -0.10 |
| Free Cash Flow | (83.28M) | (44.17M) | (52.42M) | (49.37M) | (18.46M) | (4.37M) | (3.83M) |
| FCF / Share | -1.34 | -0.82 | -1.19 | -1.19 | -0.45 | -0.10 | -0.09 |
| Operating CF | (82.23M) | (43.81M) | (50.58M) | (42.92M) | (16.98M) | (4.37M) | (3.83M) |
| Total Assets | 1.01B | 1.06B | 380.41M | 364.01M | 379.82M | 16.22M | 679,000 |
| Total Debt | 22.14M | 23.02M | 24.54M | 25.30M | 194,000 | 0 | 4.00M |
| Cash & Equiv | 52.33M | 430.61M | 19.20M | 51.43M | 35.58M | 7.81M | 658,000 |
| Book Value | 956.82M | 1.02B | 344.35M | 320.74M | 366.33M | (14.64M) | (7.94M) |
| Return on Equity | -0.12 | -0.07 | -0.17 | -0.20 | -0.09 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.27M | 3.73M | 7.88M | 10.00M | 0 | 0 | 0 | 439,000 | 8.90M | 1.25M | 2.46M | 2.52M |
| Net Income | (21.97M) | (24.36M) | (31.95M) | (24.31M) | (33.86M) | (23.51M) | (20.22M) | (28.06M) | (5.96M) | (14.76M) | (11.76M) | (11.57M) |
| EPS | -0.35 | -0.39 | -0.51 | -0.39 | -0.55 | -0.38 | -0.36 | -0.51 | -0.11 | -0.30 | -0.25 | -0.25 |
| Free Cash Flow | (328,000) | (12.61M) | (28.65M) | (12.95M) | (24.29M) | (17.39M) | (16.77M) | (2.26M) | (10.12M) | (15.03M) | (10.42M) | (12.18M) |
| FCF / Share | -0.01 | -0.20 | -0.46 | -0.21 | -0.39 | -0.28 | -0.30 | -0.04 | -0.19 | -0.31 | -0.22 | -0.27 |
| Operating CF | 147,000 | (12.34M) | (28.54M) | (12.86M) | (23.81M) | (17.02M) | (16.73M) | (2.23M) | (10.02M) | (14.84M) | (9.90M) | (11.71M) |
| Total Assets | 1.01B | 1.03B | 1.01B | 1.02B | 1.03B | 1.05B | 1.06B | 695.02M | 691.41M | 688.98M | 380.41M | 386.85M |
| Total Debt | 20.99M | 21.57M | 22.14M | 22.66M | 22.19M | 22.61M | 23.02M | 23.43M | 23.82M | 24.18M | 24.54M | 24.89M |
| Cash & Equiv | 27.77M | 51.83M | 52.33M | 48.39M | 52.45M | 73.74M | 430.61M | 26.75M | 14.66M | 212.80M | 19.20M | 17.15M |
| Book Value | 927.98M | 941.53M | 956.82M | 976.55M | 990.52M | 1.01B | 1.02B | 656.10M | 657.68M | 655.76M | 344.35M | 348.95M |
| Return on Equity | -0.02 | -0.03 | -0.03 | -0.02 | -0.03 | -0.02 | -0.02 | -0.04 | -0.01 | -0.02 | -0.03 | -0.03 |
